United States-based Bon Secours Mercy Health, a Catholic health care system, has collaborated with United States-based Lirio LLC, a behavioural engagement solution, it was reported yesterday.
The strategic partnership was announced at the 38th annual JP Morgan Healthcare Conference and was initiated by a direct investment from Bon Secours Mercy Health in Lirio's behaviour change AI platform. John Starcher, president and CEO of Bon Secours Mercy Health will join Lirio's board of directors.
Both firms will co-develop new behaviour change programs that influence health decision-making for those at risk for chronic diseases, such as diabetes and hypertension. These programs will gradually be marketed and sold to other health systems globally under commercial terms agreed to between both parties. Bon Secours Mercy Health will license and install present Lirio behaviour change programs, such as women's health programs and programs that encourage the use of digital engagement tools like patient portals.
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
AROA Biosurgery completes Symphony trial in patients with diabetic foot ulcers
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Kodiak Sciences reports positive Phase 3 results for Zenkuda in diabetic retinopathy
Maze Therapeutics reports positive Phase 2 data for MZE829 in patients with AMKD
Andel launches new direct-to-employer medication platform for GLP-1s
Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026
Cedar Health Research opens new embedded research site within Texas Native Health
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Alvotech reaches global settlement over aflibercept biosimilar patents
MedPal AI announces approval to supply Eli Lilly medicines in UK
Hanmi Pharmaceutical signs distribution agreement with Laboratorios Sanfer in Mexico
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735